Paul Tudor Jones Cassava Sciences Inc Transaction History
Tudor Investment Corp Et Al
- $29 Billion
- Q1 2025
Shares
1 transactions
Others Institutions Holding SAVA
# of Institutions
138Shares Held
14.4MCall Options Held
1.67MPut Options Held
1.26M-
Black Rock Inc. New York, NY3.22MShares$7.47 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.17MShares$5.03 Million0.0% of portfolio
-
David A. Siegel Two Sigma Advisers, LP | New York, Ny909KShares$2.11 Million0.0% of portfolio
-
State Street Corp Boston, MA874KShares$2.03 Million0.0% of portfolio
-
Jpmorgan Chase & CO New York, NY790KShares$1.83 Million0.0% of portfolio
About CASSAVA SCIENCES INC
- Ticker SAVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,097,900
- Market Cap $93M
- Description
- Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...